TR199802394A3 - Proteinleri stabilize etmek için gelistirilmis proses. - Google Patents

Proteinleri stabilize etmek için gelistirilmis proses.

Info

Publication number
TR199802394A3
TR199802394A3 TR1998/02394A TR9802394A TR199802394A3 TR 199802394 A3 TR199802394 A3 TR 199802394A3 TR 1998/02394 A TR1998/02394 A TR 1998/02394A TR 9802394 A TR9802394 A TR 9802394A TR 199802394 A3 TR199802394 A3 TR 199802394A3
Authority
TR
Turkey
Prior art keywords
improved process
stabilize proteins
stabilize
proteins
improved
Prior art date
Application number
TR1998/02394A
Other languages
English (en)
Other versions
TR199802394A2 (tr
Inventor
Hellerbrand Klaus
Papadimitriou Apollon
Winter Gerhard
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26145913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR199802394(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of TR199802394A2 publication Critical patent/TR199802394A2/tr
Publication of TR199802394A3 publication Critical patent/TR199802394A3/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/963—Methods of stopping an enzyme reaction or stabilizing the test materials
TR1998/02394A 1997-11-22 1998-11-20 Proteinleri stabilize etmek için gelistirilmis proses. TR199802394A3 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97120528 1997-11-22
EP98102846 1998-02-19

Publications (2)

Publication Number Publication Date
TR199802394A2 TR199802394A2 (tr) 1999-06-21
TR199802394A3 true TR199802394A3 (tr) 1999-06-21

Family

ID=26145913

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1998/02394A TR199802394A3 (tr) 1997-11-22 1998-11-20 Proteinleri stabilize etmek için gelistirilmis proses.

Country Status (16)

Country Link
US (1) US6238664B1 (tr)
EP (1) EP0917879B1 (tr)
JP (1) JP3105494B2 (tr)
KR (1) KR100315908B1 (tr)
CN (1) CN1220270A (tr)
AR (2) AR018020A1 (tr)
AT (1) ATE220558T1 (tr)
AU (1) AU714264B2 (tr)
BR (1) BRPI9805021B8 (tr)
CA (1) CA2254145C (tr)
DE (1) DE59804785D1 (tr)
DK (1) DK0917879T3 (tr)
ES (1) ES2179414T3 (tr)
PT (1) PT917879E (tr)
TR (1) TR199802394A3 (tr)
ZA (1) ZA9810650B (tr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW570805B (en) 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
CA2400318C (en) * 2000-02-08 2005-06-14 Allergan, Inc. Botulinum toxin pharmaceutical compositions
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
US20040185040A1 (en) * 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
US20030175827A1 (en) * 2002-03-14 2003-09-18 Stillman Brett A. Stable thin film dried protein composition or device and related methods
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
AU2004216298B2 (en) * 2003-02-28 2009-04-23 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
JP2009502972A (ja) * 2005-07-29 2009-01-29 アムジエン・インコーポレーテツド タンパク質凝集を抑制する製剤
JP2010506839A (ja) * 2006-10-12 2010-03-04 ワイス エルエルシー 乳光の低減を伴う方法および組成物
KR20120027031A (ko) * 2009-06-18 2012-03-20 와이어쓰 엘엘씨 소형 모듈 면역제약용 동결건조 제제
CA3153799A1 (en) 2012-09-07 2014-03-13 Coherus Biosciences, Inc. Stable aqueous formulations of adalimumab
WO2016069173A2 (en) * 2014-09-29 2016-05-06 Cook General Biotechnology Llc Uses of trehalose in cell suspensions
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
WO2017184880A1 (en) 2016-04-20 2017-10-26 Coherus Biosciences, Inc. A method of filling a container with no headspace
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
CN111781345A (zh) * 2020-06-30 2020-10-16 上海透景生命科技股份有限公司 化学发光标记物标记抗原稳定剂及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0018609B1 (de) 1979-04-30 1983-09-21 Hoechst Aktiengesellschaft Gegen Denaturierung beständige, wässrige Protein-Lösungen, Verfahren zu ihrer Herstellung und ihre Verwendung
US4783441A (en) 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
US4362661A (en) 1979-08-09 1982-12-07 Teijin Limited Immunoglobulin composition having a high monomer content, and process for production thereof
CA1329760C (en) 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
GB8726136D0 (en) * 1987-11-07 1987-12-09 Wellcome Found Therapeutic nucleosides
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
ES2051830T3 (es) 1987-11-27 1994-07-01 Akzo Nv Solucion acuosa estable de anticuerpos.
GB8920534D0 (en) * 1989-09-11 1989-10-25 Wellcome Found Antiviral compounds
US5164296A (en) * 1990-08-31 1992-11-17 University Of Maryland At Baltimore Assay methods involving ouabain
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
RU2109290C1 (ru) * 1996-04-09 1998-04-20 Государственный научный центр вирусологии и биотехнологии "Вектор" Стабилизирующий состав для получения лиофилизированных препаратов на основе конъюгата антииммуноглобулина g и пероксидазы хрена
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern

Also Published As

Publication number Publication date
BRPI9805021B1 (pt) 2011-05-31
PT917879E (pt) 2002-12-31
CA2254145A1 (en) 1999-05-22
KR19990045460A (ko) 1999-06-25
AR034226A2 (es) 2004-02-04
EP0917879B1 (de) 2002-07-17
AR018020A1 (es) 2001-10-31
BRPI9805021A (pt) 2000-03-21
BRPI9805021B8 (pt) 2021-07-06
CA2254145C (en) 2002-10-08
ATE220558T1 (de) 2002-08-15
DE59804785D1 (de) 2002-08-22
JPH11240895A (ja) 1999-09-07
DK0917879T3 (da) 2002-11-04
TR199802394A2 (tr) 1999-06-21
KR100315908B1 (ko) 2002-04-24
US6238664B1 (en) 2001-05-29
EP0917879A3 (de) 1999-06-09
CN1220270A (zh) 1999-06-23
ZA9810650B (en) 1999-05-24
JP3105494B2 (ja) 2000-10-30
AU714264B2 (en) 1999-12-23
AU9406098A (en) 1999-06-10
ES2179414T3 (es) 2003-01-16
EP0917879A2 (de) 1999-05-26

Similar Documents

Publication Publication Date Title
ID26007A (id) Proses karbonilasi
DK20998A (da) Høstfremgangsmåde
TR199802394A3 (tr) Proteinleri stabilize etmek için gelistirilmis proses.
DE69822614D1 (de) Dna kapillare
TR199800818A3 (tr) Ikame edilmis diaminokarbonik asitler.
ATE238984T1 (de) Sulfonylaminocarbonsäuren
ID20640A (id) PROSES PEMBAKARAN NOx RENDAH
ID23316A (id) Proses karbonilasi
ID22641A (id) Proses pembuatan e-kaprolaktam
ID20274A (id) Proses untuk memproduksi diamina
ID16994A (id) Unit proses
ID25893A (id) Proses pelletisasi
ID25547A (id) Proses pembuatan asam l-askorbat
ID15864A (id) Proses untuk membuat urea butiran
ID22222A (id) Proses pembuatan tiazolidinadiona tersubstitusi
NO20003079D0 (no) Polymerisasjon-oppstartningsprosess
ID24830A (id) Proses untuk pengolahan laktam
ID23155A (id) Proses pembuatan eprosartan
ID24343A (id) Perbaikan bagian-bagian struktural
ID25511A (id) Proses dihidrogenasi dinitril
ID23181A (id) Proses pembuatan eprosartan
ID15862A (id) Proses
ID22662A (id) Proses pemurnian kaprolaktam
NO20003080D0 (no) Polymerisasjon-oppstartningsprosess
ID24181A (id) Proses kimia